Cubist Systematic Strategies, LLC - BIO-TECHNE CORP ownership

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.

About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Quarter-by-quarter ownership
Cubist Systematic Strategies, LLC ownership history of BIO-TECHNE CORP
ValueSharesWeighting
Q3 2023$8,817,056
-13.2%
129,529
-5.4%
0.06%
+4.8%
Q1 2023$10,161,827
+424.9%
136,970
+486.3%
0.06%
+463.6%
Q4 2022$1,936,077
-82.2%
23,360
-38.9%
0.01%
-82.0%
Q3 2022$10,858,000
+19.4%
38,232
+45.8%
0.06%
+8.9%
Q2 2022$9,092,000
+109.8%
26,230
+162.1%
0.06%
+51.4%
Q1 2022$4,333,000
-20.0%
10,006
-4.4%
0.04%
-28.8%
Q4 2021$5,417,000
-38.6%
10,470
-42.5%
0.05%
-53.2%
Q3 2021$8,821,000
-12.2%
18,204
-18.4%
0.11%
-1.8%
Q2 2021$10,047,000
+4287.3%
22,313
+3618.8%
0.11%
+3666.7%
Q1 2021$229,000
-95.5%
600
-96.3%
0.00%
-95.8%
Q4 2020$5,139,000
+376.3%
16,184
+271.7%
0.07%
+343.8%
Q3 2020$1,079,000
+84.8%
4,354
+97.0%
0.02%
+60.0%
Q2 2020$584,000
+12.5%
2,210
-19.3%
0.01%
-28.6%
Q1 2020$519,000
+95.1%
2,739
+126.2%
0.01%
+180.0%
Q4 2019$266,000
+118.0%
1,211
+94.1%
0.01%
+150.0%
Q3 2019$122,000
-97.0%
624
-96.8%
0.00%
-97.3%
Q2 2019$4,058,000
+1093.5%
19,465
+1037.0%
0.08%
+581.8%
Q1 2019$340,000
-74.1%
1,712
-80.7%
0.01%
-83.3%
Q2 2018$1,313,000
+129.5%
8,873
+134.1%
0.07%
+100.0%
Q1 2018$572,000
+46.7%
3,790
+17.5%
0.03%
+50.0%
Q3 2017$390,000
+222.3%
3,226
+192.5%
0.02%
+175.0%
Q3 2016$121,000
-40.7%
1,103
-50.1%
0.01%
-27.3%
Q4 2014$204,0002,2120.01%
Other shareholders
BIO-TECHNE CORP shareholders Q2 2022
NameSharesValueWeighting ↓
Broadcrest Asset Management, LLC 300,000$24,489,00021.05%
Montanaro Asset Management Ltd 388,800$31,737,7445.02%
Sandhill Capital Partners LLC 502,447$41,014,7753.74%
Brown Capital Management 3,160,892$258,023,6143.66%
DF DENT & CO INC 3,275,617$267,388,6403.62%
Ownership Capital B.V. 2,282,104$186,288,1503.26%
Jackson Square Partners, LLC 1,361,789$111,162,8363.24%
STONE RUN CAPITAL, LLC 88,135$7,194,4603.20%
Pembroke Management, LTD 339,591$27,720,8132.99%
Summit Creek Advisors LLC 283,693$23,157,8602.90%
View complete list of BIO-TECHNE CORP shareholders